60 results
Page 3 of 3
424B5
fhwgk4g48ua5a
2 Jan 20
Prospectus supplement for primary offering
4:50pm
S-3
esm42kqayb8
20 Dec 19
Shelf registration
4:17pm
8-K
EX-99.1
x3hufb9
24 Sep 19
Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12 Months
5:20pm
10-Q
085wcbro
9 May 19
Quarterly report
7:13am
DEF 14A
37kkp
26 Apr 19
Definitive proxy
5:00pm
10-K
tevdi001c
28 Feb 19
Annual report
1:08pm
424B5
l8hz9
25 Jan 19
Prospectus supplement for primary offering
8:01am
424B5
7rldn hfdmfk010
22 Jan 19
Prospectus supplement for primary offering
5:12pm
8-K
EX-99.2
fg54v0ffmtopvv7g
22 Jan 19
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
5:08pm
6-K
EX-99.2
nn5z4pp2y4pahrzuq4i
13 Nov 18
Current report (foreign)
6:33am
F-3
dham3jau5e
12 Oct 18
Shelf registration (foreign)
5:24pm
6-K
EX-99.2
4twv0r9p
14 Aug 18
Current report (foreign)
4:09pm
6-K
EX-99.1
auvrkv
12 Jul 18
UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors
8:07pm
6-K
EX-99.2
lmp3 tqdnsb
15 May 18
Current report (foreign)
4:24pm
20-F
xwx9eif pm9x1
15 Mar 18
Annual report (foreign)
12:00am
424B4
a1yt8zfza8mi5ajk i0
22 Jan 18
Prospectus supplement with pricing info
12:00am